Please login to the form below

Not currently logged in
Email:
Password:

José Baselga joins BMS’ board of directors

He will serve as a member of the science and technology committee

Global biopharma Bristol-Myers Squibb has appointed José Baselga to its board of directors, serving as a member of its science and technology committee.

Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and translational research.

He brings more than 30 years of clinical and research experience to his new position on the board, and his career history has seen him serve as president for the American Association for Cancer Research.

Giovanni Caforia, chairman and chief executive officer of BMS, said: “José is an internationally-recognised physician scientist in oncology with deep experience in teaching at leading academic institutions, pioneering research for targeted cancer therapies and treating patients.

“His close engagement with emerging science across biotech and shared focus on patients brings valuable contributions to helping us advance our strategy and pipeline of transformational medicines.”

7th March 2018

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...
How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....
Main image1
Global leaders in digital channels
Exploring why UK field teams are global leaders in digital channels is key to better understanding the changes in omnichannel engagement...